Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
31 August 2019 (00:00 - 00:00)
Organised by:
About the speaker
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
9 More presentations in this session
Doctor S. Drakos (Salt Lake City, US)
Professor L. Kober (Copenhagen, DK)
Professor I. Jung (Yongin, KR)
Access the full session
The Event
ESC Congress 2019
31 August - 4 September 2019
